Diabetes mellitus: a prothrombotic state Implications for outcomes after coronary revascularization

References

• Mc FaddenEPStabileERegarELate thrombosis in drug-eluting stent after discontinuation of antiplatelet therapyLancet20043641519152115500897
   PubMedGoogle Scholar
• MorenoRFernandezCHernandezRDrug-eluting stent thrombosis: results from a pooled análisis including 10 randomized studiesJ Am Coll Cardiol20054595495915766835
   PubMed Web of Science ®Google Scholar
• IakovouISchmidtTBonizzoniEIncidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stentsJAMA20052932126213015870416
   PubMed Web of Science ®Google Scholar
• OngATMcFaddenEPRegarEde JaegerePPvan DomburgRTSerruysPWLate angiographic stent thrombosis (LAST) events with drug-eluting stentsJ Am Coll Cardiol2005452088209215963413
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJTIFryETDeLagoAEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA20022882411242012435254
   PubMed Web of Science ®Google Scholar
• CheneauEleborgneLMintzGSKotaniJPichardADSatlerLFCanosDCastagnaMWeissmanNJWaksmanRPredictors of subacute stent thrombosis: results of a systematic intravascular ultrasound studyCirculation2003108434712821553
   PubMed Web of Science ®Google Scholar
• FujiiKCarlierSGMintzGSStent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound studyJ Am Coll Cardiol20054599599815808753
   PubMed Web of Science ®Google Scholar
• ColaCSabatéMRevascularization in high risk patients: diabetes mellitusMinerva Cardioangiol20075555757717912163
   PubMedGoogle Scholar
• GurbelPACallahanKPMalininAISerebruanyVLGillisJCould stent design affect platelet activation? Results of the Platelet Activation in STenting (PAST) studyJ Invasive Cardiol20021458458912368510
   PubMedGoogle Scholar
• NebekerJRVirmaniRBennettCLHypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and reports (RADAR) projectJ Am Coll Cardiol20064717518116386683
   PubMed Web of Science ®Google Scholar
• SteffelJLatiniRAAkhmedovARapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent designCirculation20051122002201116172265
   PubMed Web of Science ®Google Scholar
• StahliBECamiciGGSteffelJPaclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activationCirc Res20069914915516794185
   PubMed Web of Science ®Google Scholar
• FinnAVKolodgieFDHarnekJDifferential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stentsCirculation200511227027815998681
   PubMed Web of Science ®Google Scholar
• MatterCMRozenbergIJaschkoAEffect of tacrolimus or sirolimus on proliferation of vascular smooth muscle and endothelial cellsJ Cardiovasc Pharmacol20064828629217204907
   PubMedGoogle Scholar
• ParkDWParkSWParkKHFrequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-upAm J Cardiol20069835235616860022
   PubMed Web of Science ®Google Scholar
• AngiolilloDJAntiplatelet therapy in type 2 diabetes mellitusCurr Opin Endocrinol Diabetes Obes20071412413117940430
   PubMedGoogle Scholar
• VinikAErbasTSun ParkTNolanRPittengerGPlatelet dysfunction and type II diabetesDiabetes Care2001241476148511473089
   PubMed Web of Science ®Google Scholar
• FerroniPBasiliSFalcoADavìGPlatelet activation in type 2 diabetes mellitusJ Thromb Haemost200421282129115304032
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoESabateMImpact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseJ Am Coll Cardiol2007501541154717936152
   PubMed Web of Science ®Google Scholar
• WatalaCGolanskiJPlutaJReduced sensitivity of platelet from type 2 diabetic patients to acetylsalicylic (aspirin)-its relation to metabolic controlJ Thromb Res2004113101113
   PubMed Web of Science ®Google Scholar
• MoriTAVandongenRDouglasAJMcCullochRKBurkeVDifferential effect of aspirin on platelet aggregation in IDDMDiabetes1992412612661551486
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEInfluence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary internventionAm J Cardiol200697384316377281
   PubMed Web of Science ®Google Scholar
• AngiolilloDJBernardoERamirezCInsulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatmentJ Am Coll Cardiol20064829830416843179
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEClopidogrel responders and interindividual variability in platelet inhibition following a high clopidogrel loading dose regimen during coronary interventionEur Heart J2004251903191015522469
   PubMed Web of Science ®Google Scholar
• AngiolilloDJShoemakerSBDesaiBRandomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery diseaseCirculation200711570871617261652
   PubMed Web of Science ®Google Scholar
• KingHAubertREHermanWHGlobal burden of diabetes, 1995–2025: prevalence, numerical estimates, and projectionsDiabetes Care199821141414319727886
   PubMed Web of Science ®Google Scholar
• NathanDMLong-term complications of diabetes mellitusN Engl J Med1993328167616858487827
   PubMed Web of Science ®Google Scholar
• BrandFNAbbottRDKannelWBDiabetes, intermittent claudication, and risk of cardiovascular eventsDiabetes1989385045092925008
   PubMed Web of Science ®Google Scholar
• StamlermJVaccaroONeatonJDWentworthDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care1993164344448432214
   PubMedGoogle Scholar
• PahorMPsatyBMFurbergCDNew evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetesJ Cardiovasc Pharmacol199832Suppl 2S18S239736437
   PubMedGoogle Scholar
• ReavenGRole of insulin resistance in human diseaseDiabetes198837159516073056758
   PubMed Web of Science ®Google Scholar
• GrantPJDiabetes mellitus as a prothrombotic conditionJ Inter Med2007262157172
   PubMed Web of Science ®Google Scholar
• Juhan-VagueIRoulCAlessiMArdissoneJHeimMVaguePIncreased plasminogen activator inhibitor activity in non insulin dependent diabetic patients. Relationship with plasma insulinThromb Haemost1989613703732678583
   PubMed Web of Science ®Google Scholar
• WagnerDCell biology of von Willebrand factorAnnu Rev Cell Biol199062172462275814
   PubMedGoogle Scholar
• CorrettiMAndersonTBenjaminEGuidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task ForceJ Am Coll Cardiol20023925726511788217
   PubMed Web of Science ®Google Scholar
• PerticoneFCaravoloRCandigliotaMObesity and body fat distribution induce endothelial dysfunction by oxidativestress. Protective effect of vitamin CDiabetes20015015916511147782
   PubMed Web of Science ®Google Scholar
• TaylorAPathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitusEndocrinol Metab Clin North Am20013098399711727407
   PubMed Web of Science ®Google Scholar
• GryglewskiRBottingRVaneJMediators produced by the endothelial cellHypertension1988125305483060428
   PubMed Web of Science ®Google Scholar
• HajekAJoistJBakerRJarrettLDemonstration and partial characterization of insulin receptors in human plateletsJ Clin Invest19796310601065447828
   PubMed Web of Science ®Google Scholar
• TrovatiMAnfossiGInfluence of insulin and insulin resistance on platelet and vascular smooth muscle cell functionJ Diabetes Complications200216354011872364
   PubMed Web of Science ®Google Scholar
• WesterbackaJYki-JarvinenHRissanenAVehkavaaraSSyrjälä MRLInhibition of platelet-collagen interaction. An in vivo action of insulin is abolished by insulin resistance in obesityArterioscler Thromb Vasc Biol20022216717211788478
   PubMed Web of Science ®Google Scholar
• KrollMSchaferABiochemical mechanisms of platelet activationBlood198974118111952669994
   PubMed Web of Science ®Google Scholar
• BaldiSNataliABuzzigoliGGavlanASironiAFerranniniEIn vitro effect of insulin on intracellular calcium concentrations: relation to insulin resistanceMetabolism199645140214078931646
   PubMed Web of Science ®Google Scholar
• KhechaiFOllivierVBrideyFEffect of advanced glycation end product-modified albumin on tissue factor expression by monocytesArterioscler Vasc Biol19971728852890
   PubMedGoogle Scholar
• Lieuw-A-FaMvan HinsberghVTeerlinkTIncreased levels of N(epsilon)-(carboxyethyl) lysine in type 1 diabetic patients with impaired renal function:correlation with markers of endothelial dysfunctionNephrol Dial Transplant20041963163614767019
   PubMed Web of Science ®Google Scholar
• WatalaCMay the alterations in lipid fluidity-mediated platelet hypersensitivity contribute to accelerated aging of platelets in diabetes mellitus?Med Hypotheses1991361421451779916
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists CollaborationCollaborative meta-analyses of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ2002324718611786451
   PubMed Web of Science ®Google Scholar
• SmithJBWillisALAspirin selectively inhibits prostaglandin production in human plateletsNat New Biol19712312352375284361
   PubMedGoogle Scholar
• PatrignaniPFilabozziPPatronoCJSelective cumulative inhibition of platelet thromboxane production by low-dose aspirin in hearlthy subjectsClin Invest19826913661372
   Google Scholar
• ColwellJAmerican Diabetes Association. Aspirin therapy in diabetes (Position Statement)Diabetes Care200326S87S8812502626
   PubMedGoogle Scholar
• Antiplatelet Trialists CollaborationCollaborative overview of randomized trials of antiplatelets therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ1994308811068298418
   PubMed Web of Science ®Google Scholar
• PearsonTABlairSNDanielsSRAHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseasesCirculation200210638839112119259
   PubMed Web of Science ®Google Scholar
• Collaborative Group of the Primary Prevention ProjectLow-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practiceLancet2001357899511197445
   PubMed Web of Science ®Google Scholar
• Physicians’ Health Study Research GroupFinal report on the aspirin component of the ongoing Physicians’Health StudyN Engl J Med19893211291352664509
   PubMedGoogle Scholar
• ETDRS InvestigatorsAspirin effects on mortality and morbidity in patients with diabetes mellitus: Early Treatment Diabetic Retinopathy Study ReportJAMA1992268129213001507375
   PubMed Web of Science ®Google Scholar
• HanssonLZanchettiACarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertensive optimal treatment randomized trialLancet1998351175517629635947
   PubMed Web of Science ®Google Scholar
• PamukcuBA review of aspirin resistance: definition, possible mechanisms, detection with platelet function tests, and its clinical outcomesJ Thromb Thrombolysis20072321322217186390
   PubMedGoogle Scholar
• BarnesGDLiJKline-RogersEDual antiplatelet agent failure: a new syndrome or clinical nonentity?Am Heart J200715473273517893001
   PubMed Web of Science ®Google Scholar
• MacchiLChristiaensLBrabantSResistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphateThromb Res200210811511912590946
   PubMedGoogle Scholar
• ZimmermannNWenkAKimUFunctional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgeryCirculation200310854254712874188
   PubMed Web of Science ®Google Scholar
• MichelsonADPlatelet function testing in cardiovascular diseasesCirculation2004110e489e49315533872
   PubMedGoogle Scholar
• TantryUSBlindenKPGurbelPAOverstimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulationJ Am Coll Cardiol2005461705170916256872
   PubMed Web of Science ®Google Scholar
• MasonPJJacobsAKFreedmanJEAspirin resistance and atherothrombotic diseaseJ Am Coll Cardiol20054698699316168280
   PubMed Web of Science ®Google Scholar
• HurlenMSeljeflotIArnesenHIncreased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirinThromb Res20009948749410973679
   PubMedGoogle Scholar
• KawasakiTOzekiYIgawaTKambayashiJIncreased platelet sensitivity to collagen in individuals resistant to low dose aspirinStroke20003159159510700490
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEInfluence of aspirin resistance on platelet function-profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary interventionAm J Cardiol200697384316377281
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEPlatelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatmentDiabetes2005542430243516046311
   PubMed Web of Science ®Google Scholar
• DichiaraJBlindenKPTantryUSThe effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) studyDiabetes2007563014301917848625
   PubMed Web of Science ®Google Scholar
• Catella-LawsonFReillyMKapoorSCyclooxygenase inhibitors and the platelet effects of aspirinN Engl J Med20013451809181711752357
   PubMed Web of Science ®Google Scholar
• CipolloneFCiabattoniGPatrignaniPOxidant stress and aspirin insensitivity thromboxane biosynthesis in severe unstable anginaCirculation20001021007101310961965
   PubMed Web of Science ®Google Scholar
• MacchiLChristiaensLBrabantSResistance in vitro to low-dose aspirin is associated with platelet PlA1 (GPIIIa) polymorphism but not with C807T (GPIa/IIa) and C-5T kozak (GPIbα) polymorphismsJ Am Coll Cardiol2003421115111913678940
   PubMed Web of Science ®Google Scholar
• QuinnMTopolEJCommon variations in platelet glycoproteins: pharmacogenomic implicationsPharmacogenomics2001234135211722284
   PubMedGoogle Scholar
• EikelboomJWHirshJWeitzJIJohnstonMYiQYusufSAspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular eventsCirculation20021051650165511940542
   PubMed Web of Science ®Google Scholar
• SaccoMPellegriniFRoncaglioniMCAvanziniFTognoniGNicolucciAPrimary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trialDiabetes Care2003263264327214633812
   PubMed Web of Science ®Google Scholar
• QuinnMJFitzgeraldDJTiclopidine and clopidogrelCirculation19991001667167210517740
   PubMed Web of Science ®Google Scholar
• BertrandMERupprechtHJUrbanPGershlickAHCLASSICS InvestigatorsDouble-blond study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)Circulation200010262462910931801
   PubMed Web of Science ®Google Scholar
• SabatineMSCannonCPGibsonCMClopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Addition of Clopidogrel to aspirin and fibrinolytis therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 InvestigatorsN Engl J Med20053521179118915758000
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJTCREDO InvestigatorsClopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA20022882411242012435254
   PubMed Web of Science ®Google Scholar
• YusufSZhaoFMethaSRClopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevationN Engl J Med200134549450211519503
   PubMed Web of Science ®Google Scholar
• BraunwaldEAntmanEMBeasleyJMAmerican College of Cardiology, American Heart AssociationCommittee on the management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients with Unstable Angina)J Am Coll Cardiol2002401366137412383588
   PubMed Web of Science ®Google Scholar
• ChenZMJiangLXChenYPCOMMIT (ClOpidogrel and metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trialLancet20053661607162116271642
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering CommitteeA randomized blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)Lancet1996348132913398918275
   PubMed Web of Science ®Google Scholar
• BhattDMarsoSHirschAAmplified benefit of clopidogrel versus aspirin in patients with diabetes mellitusAm J Cardiol20029062562812231089
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering CommitteeA randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events. (CAPRIE)Lancet1996348132913398918275
   PubMed Web of Science ®Google Scholar
• HochholzerWTrenkDFrundiDNeumannFJWhole blood aggregometry for evaluation of the antiplatelet effects of clopidogrelThromb Res200711928529116603231
   PubMedGoogle Scholar
• AngiolilloDJFernandez-OrtizABernardoEAlfonsoFMacayaCBassTACostaMAVariability in individual responsiveness to clopidogrel: clinical implications, management and future perspectivesJ Am Coll Cardiol2007491505151617418288
   PubMed Web of Science ®Google Scholar
• WiviottSDAntmanEMClopidogrel resistance: a new chapter in a fast-moving storyCirculation20041093064306715226220
   PubMed Web of Science ®Google Scholar
• GurbelPABlindenKPHiattBLO’ConnorCMClopidogrel for coronary stenting. Response, variability, drug resistance and the effect of pre-treatment platelet reactivityCirculation20031072908291312796140
   PubMed Web of Science ®Google Scholar
• JaremoPLindahlTLFranssonSGRichterAIndividual variations of platelet inhibition after loading doses of clopidogrelJ Intern Med200225223323812270003
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEIdentification of low responders to a 300 mg clopidogrel loading dose in patients undergoing coronary stentingThromb Res200511510110815567460
   PubMed Web of Science ®Google Scholar
• AngiolilloDJFernandez-OrtizABernardoEHigh clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variabiltyEur Heart J2004251903191015522469
   PubMed Web of Science ®Google Scholar
• GurbelPABlindenKPHayesKMYohoJAHerzogWRTantryUSThe relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stentingJ Am Coll Cardiol2005451392139615862408
   PubMed Web of Science ®Google Scholar
• GurbelPABlindenKPDurability of platelet inhibition by clopidogrelAm J Cardiol2003911123112512714161
   PubMed Web of Science ®Google Scholar
• GreselePGuglieminiGDe AngelisMAcute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type 2 diabetes mellitusJ Am Coll Cardiol2003411013102012651051
   PubMed Web of Science ®Google Scholar
• DavìGAvernaMCatalanoIBarbagalloCMGiovencoECarroccioANotarbartoloAStranoAPlatelet function in patients with type 2 diabetes mellitus: the effect of glycemic controlDiabetes Res Clin Pract198910712
   Google Scholar
• FerreiraIAEybrechtsKLMockingAIKronerCAkkermanJWIRS-1 mediates inhibition of Ca2+ mobilization by insulin via the inhibitory G-protein GiJ Biol Chem20042793254326414602724
   PubMed Web of Science ®Google Scholar
• LiuDMaierAScholzeAHigh glucose enhances transient receptor potential channel canonical type 6-dependent calcium influx in human platelets via phosphatidylinositol 3-kinase-dependent pathwayArterioscler Thromb Vasc Biol20082874675118258814
   PubMed Web of Science ®Google Scholar
• FerreiraIAMockingAIFeijgeMAPlatelet inhibition by insulin is absent in type 2 diabetes mellitusArterioscler Thromb Vasc Biol20062641742216339499
   PubMed Web of Science ®Google Scholar
• PatronoCGarcia RodriguezLALandolfiRBaigentCLow-dose aspirin for the prevention of atherothrombosisN Engl J Med20053532373238316319386
   PubMed Web of Science ®Google Scholar
• SibbingDvon BeckerathOSchomigAkastratiAvon BeckerathNDiabetes mellitus and platelet function after administration of aspirin and a single dose of clopidogrelJ Thromb Haemost200642566256816938125
   PubMedGoogle Scholar
• LotrionteMBiondi-ZoccaiGGAgostoniPMeta-analysis appraising high clopidogrel loading in patientes undergoing percuntaneous coronary interventionAm J Cardiol20071001199120617920357
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWHongMKTriple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosisJ Am Coll Cardiol2005461833183716286167
   PubMed Web of Science ®Google Scholar
• Biondi-ZoccaiGGLotrionteMAnselminoMSystematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary interventionAm Heart J20081551081108918513523
   PubMed Web of Science ®Google Scholar
• LeeSWParkSWKimYHDrug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients)J Am Coll Cardiol2008511181118718355656
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCapranzanoPGotoSA randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 studyEur Heart J2008292202221118567918
   PubMed Web of Science ®Google Scholar
• AngiolilloDJCostaMAShoemakerSBFunctional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatmentAm J Cardiol200810144044518312754
   PubMed Web of Science ®Google Scholar
• VorchheimerDABadimonJJFusterVPlatelet glycoprotein IIb/IIIa receptors antagonists in cardiovascular diseaseJAMA19992811407141410217057
   PubMed Web of Science ®Google Scholar
• WiviottSDTrenkDFrelingerALPRINCIPLE-TIMI 44 InvestigatorsPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation20071162923293218056526
   PubMed Web of Science ®Google Scholar
• WallentinLVarenhorstCJamesSPrasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery diseaseEur Heart J200829213018055486
   PubMed Web of Science ®Google Scholar
• WiviottSDBrunwaldEMcCabeCHTRITON-TIMI 38 InvestigatorsPrasugrel versus clopidogrel in patients with acute coronary syndromesNew Engl J Med20073572001201517982182
   PubMed Web of Science ®Google Scholar
• LempGFVander ZwaagRHughesJPAssociation between the severity of diabetes mellitus and coronary arterial atherosclerosisAm J Cardiol198760101510193314456
   PubMed Web of Science ®Google Scholar
• GorayaTYLeibsonCLPalumboPJCoronary atherosclerosis in diabetes mellitus: a population-based autopsy studyJ Am Coll Cardiol20024094695312225721
   PubMed Web of Science ®Google Scholar
• FlahertyJDDavidsonCJDiabetes and coronary revascularizationJAMA20052931501150815784875
   PubMed Web of Science ®Google Scholar
• KarhaJBhattDLPercutaneous coronary intervention in diabeticsRev Endocr Metab Disord2004527728515211100
   PubMedGoogle Scholar
• DharamJKumbhaniSMBavryAAKamdarAHeltonTJBhattDLThe effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trialsshowedAm Heart J200815564064718371470
   PubMedGoogle Scholar
• SabatéMJimenez-QuevedoPAngiolilloDJRandomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trialCirculation20051122175218316203930
   PubMed Web of Science ®Google Scholar
• DibraAKastratiAMehilliJISAR-DIABETES Study InvestigatorsPaclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patientsN Engl J Med200535366367016105990
   PubMed Web of Science ®Google Scholar
• TomaiFReimersBDe LucaLHead-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter studyDiabetes Care200831151917909090
   PubMedGoogle Scholar
• BaumgartDKlaussVBaerFSCORPIUS Study InvestigatorsOne-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patientsJ Am Coll Cardiol2007501627163417950142
   PubMedGoogle Scholar
• MarestaAVaraniEBalducelliMDESSERT InvestigatorsComparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study)Am J Cardiol20081011560156618489933
   PubMedGoogle Scholar
• DaemenJWenaweserPTsuchidaKEarly and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort studyLancet200736966767817321312
   PubMed Web of Science ®Google Scholar
• StoneGWMosesJWEllisSGSafety and efficacy of sirolimus and paclitaxel-eluting coronary stentsN Engl J Med2007356998100817296824
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJPacheJAnalysis of 14 trials comparing sirolimus-eluting stents with bare-metal stentsN Engl J Med20073561030103917296823
   PubMed Web of Science ®Google Scholar
• MauriLHsiehW-HMassaroJMHoKKLD’AgostinoRCutlipDEStent thrombosis in randomized clinical trials of drug-eluting stentsN Engl J Med20073561020102917296821
   PubMed Web of Science ®Google Scholar
• StettlerCWandelSAllemannSOutcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysisLancet200737093794817869634
   PubMed Web of Science ®Google Scholar
• HodgsonJMStoneGWLincoffAMSociety for Cardiovascular Angiography and InterventionsLate stent thrombosis: considerations and practical advice for the use of drug-eluting stents: a report from the Society for Cardiovascular Angiography and Interventions Drug-eluting Stent Task ForceCatheter Cardiovasc Interv200769332733317219373
   PubMedGoogle Scholar
• KapurAMalikISBaggerJPThe Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and designAm Heart J2005149131915660030
   PubMed Web of Science ®Google Scholar
• FREEDOM IFuture revascularization evaluation in patients with Diabetes Mellitus: optimal management of multivessel disease. FREEDOM Trial, 2006.
   Google Scholar
• OngATHoyeAAokiJThirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantationJ Am Coll Cardiol20054594795315766834
   PubMed Web of Science ®Google Scholar
• CutlipDEWindeckerSMehranRClinical end points in coronary stent trials: a case for standardized definitionsCirculation20071152344235117470709
   PubMed Web of Science ®Google Scholar
• LuscherTFSteffelJEberliFRDrug-eluting stent and coronary thrombosis: biological mechanisms and clinical implicationsCirculation20071151051105817325255
   PubMed Web of Science ®Google Scholar
• VirmaniRGuagliumiGFarbALocalized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?Circulation200410970170514744976
   PubMed Web of Science ®Google Scholar
• WestNERuygrokPNDiscoCMClinical and angiographic predictors of restenosis after stent deployment in diabetic patientsCirculation200410986787314757691
   PubMed Web of Science ®Google Scholar
• NilesNWMcGrathPDMalenkaDGroup. NNECDSSurvival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective studyJ Am Coll Cardiol2001371008101511263600
   PubMed Web of Science ®Google Scholar
• LincoffAMImportant triad incardiovascular medicine: diabetes, coronary intervention and platelet glycoprotein IIb/IIIa receptor blokadeCirculation20031071556155912654616
   PubMedGoogle Scholar
• GurbelPABlindenKPSamaraWYohoJAHayesKFisshaMZTantryUSClopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST studyJ Am Coll Cardiol2005461827183216286166
   PubMed Web of Science ®Google Scholar
• BuonamiciPMarcucciRMiglioriniAImpact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJ Am Coll Cardiol2007492312231717572245
   PubMed Web of Science ®Google Scholar
• de la Torre-HernándezJMAlfonsoFHernándezFDrug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos)J Am Coll Cardiol20085198699018325436
   PubMed Web of Science ®Google Scholar
• KumbhanDJBavryAAKamdarARHeltonTJBhattDLThe effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trialsAm Heart J200815564064718371470
   PubMedGoogle Scholar
• SpauldingCDaemenJBoersmaECutlipDESerruysPWA pooled analysis of data comparing sirolimus-eluting stents with baremetal stentsN Engl J Med200735698999717296825
   PubMed Web of Science ®Google Scholar
• UrbanPGershlickAHGuagliumiGSafety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registryCirculation20061131434144116534015
   PubMed Web of Science ®Google Scholar
• MachecourtJDanchinNLablancheJRisk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and non-diabetic patients. The EVASTENT matched-cohort registryJ Am Coll Cardiol20075050150817678732
   PubMed Web of Science ®Google Scholar
• KirtaneAJEllisSGDawkinsKDPaclitaxel-eluting coronary stents in patients with diabetes mellitus pooled analysis from 5 randomized trialsJ Am Coll Cardiol20085170871518279734
   PubMedGoogle Scholar
• KuchulakantiPKChuWWTorgusonRCorrelates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stentsCirculation20061131108111316490815
   PubMed Web of Science ®Google Scholar